US Treasury proposes broad curbs on investment in Chinese biotech

· Health · United States · China

The US Treasury Department has proposed draft rules that would sharply limit what drug and biotech assets American companies and venture capitalists can invest in or strike deals for in much of China's biotech sector. The proposal would subject outbound licensing deals with Chinese biotech companies to additional scrutiny. The move follows months of rumors that Washington was preparing such a rule, and it lands as US-China tensions over biotechnology have been building. The immediate effect would fall on cross-border licensing, venture funding and partnering arrangements that many Chinese drug developers rely on to reach global markets, and on US investors who have used those deals to access China's pipeline of experimental medicines. The details remain in draft form, so the scope of what is covered, and how licensing versus equity investment is treated, will determine how much of the sector's deal flow is affected.

Why it matters：Cross-border licensing has become the main artery linking Chinese drug discovery to global pharma, so restricting it would reshape dealmaking, valuations and pipeline access across the industry.

Key points

  • The draft rules would cover both investments and deals for drug and biotech assets.
  • Outbound licensing agreements with Chinese biotech companies would face added scrutiny.
  • The proposal is still in draft, so its final scope is unresolved.

Sources (original reporting)

More stories from this day